Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAVEL ALEKSANDER LEVIN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1528352614
CMS profile
1306534
Location
PEARLAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$10,391.11

199 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,050.00 4
Food and Beverage $4,367.50 184
Long term medical supply or device loan $947.89 10
Education $25.72 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $3,042.04 13
BeiGene USA, Inc. $2,275.00 2
Novartis Pharmaceuticals Corporation $1,335.68 26
PFIZER INC. $402.94 16
Merck Sharp & Dohme LLC $378.21 15
Celgene Corporation $246.54 11
E.R. Squibb & Sons, L.L.C. $223.28 11
ABBVIE INC. $184.08 8
Janssen Biotech, Inc. $162.32 7
GENZYME CORPORATION $154.83 5
Takeda Pharmaceuticals U.S.A., Inc. $153.95 5
Daiichi Sankyo Inc. $151.79 6
Gilead Sciences, Inc. $146.22 9
Astellas Pharma US Inc $137.30 7
Alexion Pharmaceuticals, Inc. $103.19 4
GlaxoSmithKline, LLC. $96.27 4
SOBI, INC $94.15 3
PUMA BIOTECHNOLOGY, INC. $77.69 4
Genentech USA, Inc. $74.01 3
Rigel Pharmaceuticals, Inc. $65.44 2
Regeneron Healthcare Solutions, Inc. $63.00 2
Deciphera Pharmaceuticals Inc. $60.10 2
Karyopharm Therapeutics Inc. $58.55 3
Exelixis Inc. $51.58 2
Lilly USA, LLC $50.51 2
Incyte Corporation $50.27 3
ARRAY BIOPHARMA INC $48.92 2
TAIHO ONCOLOGY, INC. $48.56 2
Tempus AI, Inc $43.38 2
Eisai Inc. $36.85 2
EMD Serono, Inc. $31.56 1
Adaptive Biotechnologies Corporation $30.29 1
TerSera Therapeutics LLC $30.16 1
SpringWorks Therapeutics, Inc. $30.10 2
Bayer Healthcare Pharmaceuticals Inc. $29.59 1
JAZZ PHARMACEUTICALS INC. $25.93 1
PharmaEssentia USA Corporation $25.79 1
Janssen Pharmaceuticals, Inc $25.72 1
SERVIER PHARMACEUTICALS LLC $24.62 1
ADC Therapeutics America, Inc. $23.42 1
Boston Scientific Corporation $22.85 1
Stemline Therapeutics Inc. $22.28 1
Aveo Pharmaceuticals, Inc. $17.71 1
Amgen Inc. $17.62 1
Amneal Pharmaceuticals LLC $16.82 1

Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAVEL ALEKSANDER LEVIN

NPI 1528352614 · CMS profile ID 1306534

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

PEARLAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1528352614?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAVEL ALEKSANDER LEVIN, NPI 1528352614, CMS profile ID 1306534. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1528352614?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). PAVEL ALEKSANDER LEVIN, NPI 1528352614, CMS profile ID 1306534. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1528352614?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
PAVEL ALEKSANDER LEVIN, NPI 1528352614, CMS profile ID 1306534, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 199 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1528352614?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

199 matching records · $10,391.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 199 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 199.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $24.7009/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086977298 CMS
PFIZER INC. $25.6209/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131358514 CMS
Merck Sharp & Dohme LLC $23.2809/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141626473 CMS
E.R. Squibb & Sons, L.L.C. $20.5809/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101360474 CMS
E.R. Squibb & Sons, L.L.C. $19.1309/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101360470 CMS
Gilead Sciences, Inc. $7.3009/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133803268 CMS
Takeda Pharmaceuticals U.S.A., Inc. $32.9709/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144961670 CMS
PFIZER INC. $20.5809/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131358626 CMS
PFIZER INC. $28.7309/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131980397 CMS
Astellas Pharma US Inc $19.0609/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139400493 CMS
Celgene Corporation $29.8908/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101118381 CMS
Novartis Pharmaceuticals Corporation $19.6008/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086977276 CMS
Stemline Therapeutics Inc. $22.2808/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142962864 CMS
ABBVIE INC. $21.3608/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104165964 CMS
Novartis Pharmaceuticals Corporation $83.3308/23/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086977280 CMS
PFIZER INC. $22.0008/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131360342 CMS
Merck Sharp & Dohme LLC $19.7108/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141847066 CMS
Alexion Pharmaceuticals, Inc. $24.2908/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093946695 CMS
AstraZeneca Pharmaceuticals LP $21.2908/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105760469 CMS
AstraZeneca Pharmaceuticals LP $24.9008/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105337136 CMS
AstraZeneca Pharmaceuticals LP $26.7908/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104264061 CMS
E.R. Squibb & Sons, L.L.C. $23.8008/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101360464 CMS
Novartis Pharmaceuticals Corporation $34.1408/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086977270 CMS
Celgene Corporation $33.5408/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101118375 CMS
Daiichi Sankyo Inc. $29.2808/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089448404 CMS
Celgene Corporation $30.9408/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101118373 CMS
Celgene Corporation $22.3208/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101118379 CMS
Amgen Inc. $17.6207/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117610303 CMS
Novartis Pharmaceuticals Corporation $23.9807/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086977274 CMS
Karyopharm Therapeutics Inc. $19.0507/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145535114 CMS
SOBI, INC $40.4207/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141426043 CMS
Astellas Pharma US Inc $20.0907/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139372841 CMS
Lilly USA, LLC $28.8307/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135189485 CMS
Novartis Pharmaceuticals Corporation $25.8407/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086977272 CMS
Merck Sharp & Dohme LLC $27.4107/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141845145 CMS
SpringWorks Therapeutics, Inc. $14.1307/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085805965 CMS
AstraZeneca Pharmaceuticals LP $33.8507/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105395746 CMS
Gilead Sciences, Inc. $21.1007/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133803266 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.0007/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144961668 CMS
SpringWorks Therapeutics, Inc. $15.9707/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085805963 CMS
Lilly USA, LLC $21.6807/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135280379 CMS
Novartis Pharmaceuticals Corporation $99.7007/15/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086977296 CMS
Janssen Biotech, Inc. $23.3907/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078746588 CMS
ADC Therapeutics America, Inc. $23.4207/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121193771 CMS
TerSera Therapeutics LLC $30.1607/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144717551 CMS
EMD Serono, Inc. $31.5607/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120244225 CMS
Regeneron Healthcare Solutions, Inc. $37.6706/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114099588 CMS
Incyte Corporation $19.5606/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141301101 CMS
GENZYME CORPORATION $28.1006/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139907535 CMS
GlaxoSmithKline, LLC. $21.6006/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116333383 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,035.22 24
PY2020 $175.84 7
PY2021 $211.78 6
PY2022 $4,692.03 65
PY2023 $4,085.73 173
PY2024 $10,391.11 199
PY2025 $8,331.36 176

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $169,413.92 24
PY2024 Principal investigator $179,892.31 6
PY2023 Principal investigator $29,698.33 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715585
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715587
Principal investigator 1 PFIZER INC. $3,187.76 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715589
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715669
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715671
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715753
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715755
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715757
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715919
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Texas Oncology Gulf Coast
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715921
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,725.00 10/31/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185538827
Principal investigator 1 PFIZER INC. $957.00 10/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228727093
Principal investigator 1 PFIZER INC. $1,125.00 09/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228762180
Principal investigator 1 Eli Lilly and Company $0.24 07/24/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187892796
Principal investigator 1 Coherus Oncology, Inc. $23,500.00 07/23/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
CHS38802 No dispute reported 06/30/2026 1235252702
Principal investigator 1 PFIZER INC. $957.00 07/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228748735
Principal investigator 1 ABBVIE INC. $19,500.00 07/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (AndroMETa-CRC) No dispute reported 06/30/2026 1202495847
Principal investigator 1 PFIZER INC. $1,125.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228763815
Principal investigator 1 Eli Lilly and Company $26,799.00 04/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
CYCLONE 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1187892004
Principal investigator 1 PFIZER INC. $957.00 04/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750999
Principal investigator 1 Eli Lilly and Company $30,804.00 01/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187892742
Principal investigator 1 Eli Lilly and Company $4,248.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
CYCLONE 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1187890548
Principal investigator 1 Eli Lilly and Company $45,328.68 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION No dispute reported 06/30/2026 1187892704
Principal investigator 1 PFIZER INC. $957.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228751003